Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937286 | 1.00 | AKR1B1 (0.38) | AKR1B1KDM1APTPN1HDAC1HDAC6 | |
| SCHEMBL5506992 | 0.75 | CA1 (0.36) | HDAC1HDAC6CA1CA2VRK1 | |
| SCHEMBL28192070 | 0.75 | CA1 (0.36) | KDM1AHDAC1HDAC6KDM1BCA1 | |
| SCHEMBL31507839 | 0.75 | AKR1B1 (0.41) | AKR1B1KDM1APTPN1KDM1BCA1 | |
| SCHEMBL18614485 | 0.74 | CA1 (0.35) | AKR1B1KDM1AHDAC1HDAC6KDM1B | |
| SCHEMBL23899944 | 0.71 | AKR1B1 (0.38) | AKR1B1PTPN1CA1CA2CA4 | |
| SCHEMBL26981490 | 0.71 | KDM1A (0.33) | KDM1AHDAC1HDAC6KDM1BCA1 | |
| SCHEMBL14576957 | 0.71 | CA1 (0.33) | AKR1B1KDM1AHDAC1HDAC6KDM1B | |
| SCHEMBL17797154 | 0.70 | CA1 (0.48) | AKR1B1KDM1AHDAC1HDAC6KDM1B | |
| SCHEMBL11591491 | 0.70 | VRK1 (0.38) | HDAC1HDAC6VRK1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | AKR1B1 3240/4885KDM1A 2745/4885PTPN1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.